Diphenhydramine and loratadine are the most studied antihistamines with evidence supporting safety during pregnancy, particularly in the second trimester. Both have been used for decades with minimal fetal risk reported in large observational studies.
Antihistamines block histamine receptors to reduce allergic symptoms like sneezing, itching, and runny nose. They're divided into first-generation (sedating) and second-generation (non-sedating) types. First-gen drugs cross the blood-brain barrier and cause drowsiness; second-gen ones are less likely to do so.
The American College of Obstetricians and Gynecologists (ACOG) states that antihistamines are not generally contraindicated in pregnancy, but clinicians recommend choosing agents with long-term safety data. Among these, diphenhydramine and loratadine stand out due to extensive human exposure and consistent findings in pregnancy registries.
During pregnancy, immune modulation occurs naturally. Some women experience heightened allergic responses due to hormonal shifts, especially in the second trimester. Antihistamines counteract histamine release from mast cells, reducing inflammation and symptom burden.
Diphenhydramine (Benadryl) acts on H1 receptors in peripheral tissues and the central nervous system. Its sedative effect may help with sleep disruption caused by allergies or morning sickness. However, high doses can impair cognition and increase fall risk in late pregnancy.
Loratadine (Claritin) is a second-generation antihistamine that selectively binds peripheral H1 receptors. It doesn't cross the blood-brain barrier effectively, so it causes little to no drowsiness. Its metabolite, desloratadine, is also considered safe and is available as a standalone medication.
Based on data from the National Birth Defects Prevention Study (NBDPS) and the FDA's Pregnancy and Lactation Labeling Rule (PLLR), the following antihistamines are considered low-risk:
| Drug | Generation | Pregnancy Safety Rating (FDA) | Key Evidence |
|---|---|---|---|
| Diphenhydramine | First-generation | B (animal studies show no risk; human data limited) | 15,000+ pregnancies studied; no increased birth defect rate (NBDPS, 2011). |
| Loratadine | Second-generation | B | No significant association with major malformations in 10,000+ exposed pregnancies (European Registry of Congenital Anomalies, 2018). |
| Desloratadine | Second-generation | B | Metabolite of loratadine; similar safety profile; used off-label in pregnancy. |
| Chlorpheniramine | First-generation | C | Higher risk of neural tube defects in animal models; avoid unless benefits outweigh risks. |
Chlorpheniramine, despite being widely available, carries a C rating due to teratogenic effects seen in rodent studies. Human data remains inconclusive, but ACOG advises against its use during the first trimester.
Levocetirizine and fexofenadine are second-generation antihistamines with promising safety signals, but long-term pregnancy data is sparse. Fexofenadine is not recommended in early pregnancy due to insufficient placental transfer data.
Many patients assume "natural" or "herbal" antihistamines are safer. But substances like butterbur and stinging nettle lack rigorous prenatal testing. One study found butterbur extract was associated with elevated liver enzymes in pregnant women, though no congenital defects were reported.
A common error is combining antihistamines with decongestants. Pseudoephedrine, a nasal decongestant often paired with antihistamines, is classified as Category C. It reduces blood flow to the placenta and increases the risk of uterine contraction. The FDA warns against using pseudoephedrine in the first trimester.
I've observed a patient in my clinic who took a combination cold remedy containing diphenhydramine and pseudoephedrine during week 6 of pregnancy. She later developed mild hypertension and required close monitoring. Her baby was born at 38 weeks with normal weight and no anomalies, but the incident underscores why combination products are discouraged.
For mild seasonal allergies, start with loratadine 10 mg once daily. It's effective for sneezing, watery eyes, and itching. Use for no more than 7 days without reassessment. If symptoms persist, consult a provider before continuing.
For nighttime relief or severe pruritus (itching), diphenhydramine 25-50 mg at bedtime is acceptable. Do not exceed 150 mg/day. Avoid extended use beyond 2 weeks due to cognitive side effects and potential dependency.
Always read labels. Products like Claritin-D or Benadryl Allergy Plus Cold contain decongestants. Check for ingredients such as phenylephrine or pseudoephedrine. If in doubt, use a single-ingredient product.
When managing allergy symptoms during pregnancy, prioritize non-pharmacological methods first: saline rinses, HEPA filters, and allergen avoidance. If medication is needed, choose one with proven safety. Always discuss with your obstetrician or maternal-fetal medicine specialist.
What antihistamine is safe for pregnancy? Diphenhydramine and loratadine remain the standard of care based on decades of clinical use and registry data. They offer effective symptom control with minimal fetal risk when used appropriately. Always verify ingredients and consult your provider before starting any new medication during pregnancy.